



Contact: Cheryl Paes
Location: Philadelphia, Pa
Email: cpaes@integralmolecular.com
Tel: 215 966 6068
Website: www.integralmolecular.com



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health



National Institutes of Health Commercialization Assistance Program
(NIH-CAP)

Company Profile

Industry Sector:

Biotechnology Reagent/ Platform Company

Company Overview:

- Develop tools for research and drug development
- Provide membrane protein related products and services
- ~20 employees, located in University City Science Center, Philadelphia, Pa
- Integral has filed >15 patents on technologies
 - 3 patents on Shotgun Mutagenesis

Target Market(s): Work with pharmaceutical, biotechnology and academic customers focused on membrane protein targets

Key Value Drivers

Technology*: Shotgun Mutagenesis is a novel strategy for mapping protein structure-activity relationships by rapidly evaluating functional effects of point mutations across an entire target protein. Using a patented high-throughput expression method, thousands of point mutations of a target protein can be concurrently evaluated for functional protein activity, all at a fraction of the cost of traditional site-directed mutagenesis.

Competitive Advantage:

High throughput, comprehensive technology for mapping membrane protein interactions. Traditional mutagenesis mapping studies can be laborious and time consuming, using the shotgun mutagenesis, interaction maps can be obtained in weeks (after library preparation) rather than months to years.

Integral

Plan & Strategy:

Goal to obtain customers and technical partners. Obtain 1-2 beta customers by the end of 2009.

*Technology funded by the *NIH* and being commercialized under the NIH-CAP

Management

Leadership:

Benjamin Doranz- President and CSO
Joe Rucker- Director of Research and Development
Bridget Puffer- Director of Research Operations
Sharon Willis- Director of Lipoparticle Production
Cheryl Paes- Product Manager, Shotgun Mutagenesis

Product Pipeline

Product Development:

- Validation of production platform complete
- Proof of concept beta mutation library construction and validation complete
- Publication of 1 manuscript in a peer-reviewed journal complete
- Obtained and worked with 1 beta-customer
- Phase 1 of marketing in process